The most important include inavolisib in combination with palbociclib and fulvestrant for advanced breast cancer [90]; datopotamab deruxtecan for patients with unresectable or metastatic hormone receptor-positive (HR+) and HER2-negative breast cancer [91]; and capivasertib in combination with fulvestrant for patients with mutations in the PIK3CA, AKT1, or PTEN genes in HR+/HER2- breast cancer [92]. This evidence concerns the gene PIK3CA and breast carcinoma.